Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next?

Shares of Pharvaris N.V. (NASDAQ:PHVS) were up 3.8% on Wednesday . The stock traded as high as $27.50 and last traded at $27.2580. Approximately 174,789 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 156,850 shares. The stock had previously closed at $26.25.

Analysts Set New Price Targets

A number of research firms recently commented on PHVS. Guggenheim lifted their price objective on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Morgan Stanley upped their price objective on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Citigroup restated a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Finally, Oppenheimer increased their price target on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $40.56.

Pharvaris Stock Up 5.7%

The firm has a market capitalization of $1.45 billion, a P/E ratio of -8.64 and a beta of -2.79. The company’s 50 day moving average is $24.74 and its 200-day moving average is $22.73.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. On average, analysts predict that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. General Atlantic L.P. grew its stake in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period. Foresite Capital Management IV LLC grew its position in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after purchasing an additional 368,000 shares during the period. venBio Partners LLC increased its stake in Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after purchasing an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. increased its stake in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP raised its holdings in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.